MX2021006908A - Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo. - Google Patents
Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo.Info
- Publication number
- MX2021006908A MX2021006908A MX2021006908A MX2021006908A MX2021006908A MX 2021006908 A MX2021006908 A MX 2021006908A MX 2021006908 A MX2021006908 A MX 2021006908A MX 2021006908 A MX2021006908 A MX 2021006908A MX 2021006908 A MX2021006908 A MX 2021006908A
- Authority
- MX
- Mexico
- Prior art keywords
- thrî
- preparation
- receptor agonist
- agonist compound
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención describe un compuesto representado por la siguiente Fórmula (I) y una sal farmacéuticamente aceptable del mismo. El compuesto mejora la selectividad de THRa mientras mantiene una buena actividad agonista de THRß, mejorando así las propiedades del fármaco terminado. (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811527414.4A CN111320609A (zh) | 2018-12-13 | 2018-12-13 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
PCT/US2019/066013 WO2020123827A1 (en) | 2018-12-13 | 2019-12-12 | Thrβ receptor agonist compound and preparation method and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006908A true MX2021006908A (es) | 2021-07-07 |
Family
ID=71071432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006908A MX2021006908A (es) | 2018-12-13 | 2019-12-12 | Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo. |
Country Status (18)
Country | Link |
---|---|
US (3) | US11084802B2 (es) |
EP (1) | EP3893889A4 (es) |
JP (1) | JP2022512482A (es) |
KR (1) | KR20210102328A (es) |
CN (3) | CN111320609A (es) |
AR (1) | AR117694A1 (es) |
AU (1) | AU2019398339A1 (es) |
BR (1) | BR112021010871A2 (es) |
CA (1) | CA3120880A1 (es) |
CL (1) | CL2021001521A1 (es) |
CO (1) | CO2021008817A2 (es) |
IL (2) | IL310699A (es) |
MA (1) | MA54471A (es) |
MX (1) | MX2021006908A (es) |
PE (1) | PE20211788A1 (es) |
SG (1) | SG11202106194TA (es) |
TW (1) | TWI837244B (es) |
WO (1) | WO2020123827A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014043706A1 (en) | 2012-09-17 | 2014-03-20 | Madrigal Pharmaceuticals, Inc. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
AU2019287679B2 (en) | 2018-06-12 | 2022-04-21 | Xizang Haisco Pharmaceutical Co., Ltd. | Thyroid hormone receptor agonists and uses thereof |
AU2019357618A1 (en) | 2018-10-12 | 2021-04-29 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
CN111909137B (zh) * | 2019-05-10 | 2023-05-30 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
CN114174282A (zh) * | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
TW202128668A (zh) * | 2019-12-16 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 并環類衍生物、其製備方法及其在醫藥上的應用 |
CN115811972A (zh) * | 2020-05-13 | 2023-03-17 | 拓臻制药公司 | 肝脏病症的组合治疗 |
IL300853A (en) | 2020-08-25 | 2023-04-01 | Lilly Co Eli | SSAO inhibitor polymorphs |
WO2022053028A1 (zh) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用 |
EP4215524A1 (en) * | 2020-09-17 | 2023-07-26 | Sunshine Lake Pharma Co., Ltd. | Compound serving as thyroid hormone beta receptor agonist and uses of compound |
EP4232436A1 (en) * | 2020-10-23 | 2023-08-30 | Madrigal Pharmaceuticals, Inc. | Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues |
CA3197249A1 (en) * | 2020-11-06 | 2022-05-12 | David Craig Mcgowan | Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists |
CN116925045A (zh) * | 2020-12-15 | 2023-10-24 | 中国科学院上海药物研究所 | 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途 |
CN114685450A (zh) | 2020-12-30 | 2022-07-01 | 昆药集团股份有限公司 | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 |
KR20230152095A (ko) * | 2021-03-03 | 2023-11-02 | 테른스 파마슈티칼스, 인크. | 갑상선 호르몬 수용체 베타 작용제 화합물 |
US20230241071A1 (en) * | 2021-11-11 | 2023-08-03 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
WO2023083288A1 (en) * | 2021-11-11 | 2023-05-19 | Terns Pharmaceuticals, Inc. | TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST |
WO2023154842A1 (en) * | 2022-02-10 | 2023-08-17 | Madrigal Pharmaceuticals, Inc. | Thr beta analogs and uses thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0377903A3 (de) * | 1989-01-09 | 1991-07-17 | Bayer Ag | Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung |
US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
JP2004517851A (ja) | 2000-12-27 | 2004-06-17 | バイエル アクチェンゲゼルシャフト | 甲状腺受容体のリガンドとしてのインドール誘導体 |
US7230031B2 (en) | 2002-01-30 | 2007-06-12 | Kissei Pharmaceutical Co., Ltd. | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
AU2003225305A1 (en) | 2002-05-08 | 2003-11-11 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
FR2882750B1 (fr) | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
DK1919878T3 (da) * | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazinonderivater som thyroidhormonreceptoragonister |
BRPI1015096A2 (pt) | 2009-04-20 | 2016-05-03 | Mitsubishi Tanabe Pharma Corp | agonista de receptor beta de hormônio tireoideano |
WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
CN103958497B (zh) | 2011-11-14 | 2017-09-01 | 亚尼塔公司 | 作为AXL和c‑MET激酶抑制剂的尿嘧啶衍生物 |
CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
JP6814730B2 (ja) | 2014-09-05 | 2021-01-20 | ジェネンテック, インコーポレイテッド | 治療用化合物およびその使用 |
IL266054B2 (en) * | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
US11485729B2 (en) | 2018-01-23 | 2022-11-01 | Shenzhen Targetrx, Inc. | Substituted pyridazinone compound |
AU2019287679B2 (en) * | 2018-06-12 | 2022-04-21 | Xizang Haisco Pharmaceutical Co., Ltd. | Thyroid hormone receptor agonists and uses thereof |
WO2020041741A1 (en) | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
WO2020039076A1 (en) | 2018-08-24 | 2020-02-27 | Plastic Omnium Advanced Innovation And Research | Assembly for a fluid tank comprising a baffle and a fluid transfer line passing through the baffle |
AU2019359141A1 (en) | 2018-10-12 | 2021-04-22 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
AU2019357618A1 (en) | 2018-10-12 | 2021-04-29 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
CN111484481A (zh) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | 哒嗪酮类衍生物、其制备方法及其在医药上的用途 |
US20220162161A1 (en) | 2019-02-21 | 2022-05-26 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
CN114174282A (zh) | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
-
2018
- 2018-12-13 CN CN201811527414.4A patent/CN111320609A/zh active Pending
-
2019
- 2019-12-12 US US16/712,301 patent/US11084802B2/en active Active
- 2019-12-12 SG SG11202106194TA patent/SG11202106194TA/en unknown
- 2019-12-12 JP JP2021533640A patent/JP2022512482A/ja active Pending
- 2019-12-12 WO PCT/US2019/066013 patent/WO2020123827A1/en unknown
- 2019-12-12 BR BR112021010871-8A patent/BR112021010871A2/pt unknown
- 2019-12-12 CA CA3120880A patent/CA3120880A1/en active Pending
- 2019-12-12 CN CN201980081797.3A patent/CN113194958B/zh active Active
- 2019-12-12 TW TW108145594A patent/TWI837244B/zh active
- 2019-12-12 PE PE2021000858A patent/PE20211788A1/es unknown
- 2019-12-12 KR KR1020217021249A patent/KR20210102328A/ko unknown
- 2019-12-12 CN CN202310453989.0A patent/CN116444498A/zh active Pending
- 2019-12-12 EP EP19896475.1A patent/EP3893889A4/en active Pending
- 2019-12-12 AR ARP190103650A patent/AR117694A1/es unknown
- 2019-12-12 AU AU2019398339A patent/AU2019398339A1/en active Pending
- 2019-12-12 MA MA054471A patent/MA54471A/fr unknown
- 2019-12-12 IL IL310699A patent/IL310699A/en unknown
- 2019-12-12 MX MX2021006908A patent/MX2021006908A/es unknown
-
2020
- 2020-09-04 US US17/013,314 patent/US11034676B2/en active Active
-
2021
- 2021-05-23 IL IL283362A patent/IL283362B2/en unknown
- 2021-06-10 CL CL2021001521A patent/CL2021001521A1/es unknown
- 2021-07-02 CO CONC2021/0008817A patent/CO2021008817A2/es unknown
-
2023
- 2023-05-10 US US18/315,291 patent/US20230278988A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL283362B2 (en) | 2024-07-01 |
BR112021010871A2 (pt) | 2021-08-31 |
US20200190064A1 (en) | 2020-06-18 |
AR117694A1 (es) | 2021-08-25 |
CL2021001521A1 (es) | 2022-01-28 |
IL283362B1 (en) | 2024-03-01 |
US11084802B2 (en) | 2021-08-10 |
MA54471A (fr) | 2021-10-20 |
US11034676B2 (en) | 2021-06-15 |
TW202039470A (zh) | 2020-11-01 |
US20230278988A1 (en) | 2023-09-07 |
SG11202106194TA (en) | 2021-07-29 |
TWI837244B (zh) | 2024-04-01 |
IL283362A (en) | 2021-07-29 |
CN116444498A (zh) | 2023-07-18 |
EP3893889A1 (en) | 2021-10-20 |
PE20211788A1 (es) | 2021-09-09 |
EP3893889A4 (en) | 2022-08-03 |
CN111320609A (zh) | 2020-06-23 |
CN113194958B (zh) | 2023-05-23 |
CN113194958A (zh) | 2021-07-30 |
KR20210102328A (ko) | 2021-08-19 |
IL310699A (en) | 2024-04-01 |
JP2022512482A (ja) | 2022-02-04 |
WO2020123827A1 (en) | 2020-06-18 |
AU2019398339A1 (en) | 2021-06-10 |
CA3120880A1 (en) | 2020-06-18 |
CO2021008817A2 (es) | 2021-07-19 |
US20200399249A1 (en) | 2020-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006908A (es) | Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo. | |
EP4349840A3 (en) | Pyrazolopyridine derivative having glp-1 receptor agonist effect | |
NZ747259A (en) | Soluble c5ar antagonists | |
AU2018251118A8 (en) | Pharmaceutical composition containing MOR agonist and KOR agonist, and uses thereof | |
PH12020500446A1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
PH12016502539A1 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
ZA202208051B (en) | Protein degradation agent compound preparation method and application | |
PH12019550154A1 (en) | Azetidine derivative | |
PH12016502246B1 (en) | Carboxamide derivatives | |
MX2021015654A (es) | Antagonista del receptor 2 de prostaglandina e2 (ep2). | |
TN2016000491A1 (en) | Carboxamide derivatives. | |
MX2021007247A (es) | Derivados de rapamicina. | |
EA201892098A1 (ru) | Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения | |
WO2011132901A3 (en) | Novel benzamide derivatives | |
PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
MX2022006104A (es) | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. | |
MX2020013352A (es) | Tratamiento para migrañas. | |
MX2022005415A (es) | Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo. | |
PH12021550248A1 (en) | Borate of azetidine derivative | |
MY197142A (en) | Gonadotropin-releasing hormone receptor antagonist and use thereof | |
PH12020500233A1 (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
WO2015187850A3 (en) | Compounds and methods for treatment of ocular disorders | |
EA201991932A1 (ru) | Производное азитидина |